Novonesis stock heads into the open after double-digit gain
Published on 09/11/2026 at 06:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novonesis stock closed higher on the Copenhagen exchange on September 10, 2026, with a double-digit percent gain that reflected strong investor response to updated earnings guidance and robust organic growth. According to a note on the company, shares advanced around 10 percent on the day after management raised guidance for the year and highlighted continued momentum in core biosolutions activities, per analysis published on September 10, 2026. As Morningstar reported on September 10, 2026, the guidance upgrade followed continued stellar organic growth and sent the shares about 10 percent higher that session.
September 10, 2026 in numbers
Novonesis A/S (ISIN DK0060336014) saw its Copenhagen-listed shares close with that roughly 10 percent rise on September 10, 2026, a move that significantly outperformed its home-market benchmark index, which gained only a small fraction of that increase on the same day. Per exchange data, the strong session came with elevated trading volume compared with the recent average, underscoring how the upgraded guidance and organic growth figures drew in additional buyers. As Morningstar highlighted, the earnings release and improved outlook were central to the price move, with the note describing continued stellar organic growth and an upgraded full-year guidance range that helped justify the sharp single-session gain.
India expansion news today
Today, attention stays on Novonesis after the company announced plans to expand its Indian manufacturing footprint with a large investment that supports next-generation enzyme production. As Automotive Lead News reported on September 10, 2026, Novonesis plans to invest 6,660 crore rupees, equivalent to about 600 million euros, to expand its site in Patalganga and build a state-of-the-art facility for next-generation enzyme production. A separate report noted that this decision marks a major step in strengthening the company’s Indian operations and could influence sentiment around the stock as investors assess the long-term growth and capacity implications of the project, according to Life Science Sweden. With the guidance upgrade, strong organic growth and a sizable India expansion all in focus, Novonesis enters today’s session with several fresh catalysts that investors may continue to weigh against broader market conditions and currency movements.
